

AUM Biosciences establishes joint lab with SlgN

19 August 2020 | News

The collaboration aims to accelerate drug development and immuno-monitoring of novel oncology drugs as targeted cancer therapies

AUM Biosciences (AUM), a Singapore-headquartered clinical-stage biopharmaceutical company aiming to democratize R&D with a focus on discovering, acquiring, and developing novel therapeutics in oncology, has announced that together with A*STAR's Singapore Immunology Network (SlgN), a new joint lab will be established in Singapore, centered on drug development and immuno-monitoring of novel oncology drugs.

Housed in SlgN's premises at Biopolis, Singapore's biomedical research hub, the joint lab will focus on the discovery of novel and proprietary immune biomarkers and underlying drug mechanisms of action that will be used to better inform clinical trial design and study endpoint analysis. Combining SlgN's scientific expertise in translational immunology, preclinical, and computational research with AUM's extensive capabilities in clinical trial design and management will lead to better targeted development programs for AUM's cancer therapies.

Professor Lam Kong Peng, Executive Director of SlgN, added, "We are excited to bring SlgN's expertise in translational immunology to the joint lab to help accelerate the development of novel cancer therapies, and to support Singapore's vibrant biotech scene through our collaboration."

Cancer remains a major medical concern with one in every six deaths being related to the disease. Recent disruptive discoveries in cancer therapy have highlighted the critical role of targeting the host immune system in regulating cancer progression. The AUM – SlgN partnership is timely to synergize drug development and immune profiling efforts to advance the development of multiple small molecules through preclinical and clinical trials with the ultimate goal of bringing these novel oncology drugs to market.

Dr. Harish Dave, CMO of AUM Biosciences, stated "AUM Biosciences is delighted to partner with SlgN in this exciting public - private collaboration. This represents the coming together of the best in translational research and industry to meet a common goal of delivering effective cancer therapeutics to patients."